Samsung Biologics reports fourth quarter and fiscal year 2025 financial results

Core Insights - Samsung Biologics demonstrated stable and resilient performance in 2025, driven by disciplined execution and strong demand despite a challenging global environment [2] - The company plans to expand its manufacturing capabilities, including a new facility in the U.S., to enhance supply chain resilience and responsiveness to global client needs [2] Financial Performance - In Q4 2025, Samsung Biologics reported revenue of KRW 1,286 billion and operating profit of KRW 528 billion, with full utilization across Plants 1 to 4 contributing to this performance [3] - For the full fiscal year 2025, the company achieved revenue of KRW 4,557 billion, reflecting a year-over-year increase of 30.3% [4] - Operating profit for FY 2025 was KRW 2,069.2 billion, representing a 56.6% increase compared to the previous year [4] - EBITDA for FY 2025 reached KRW 2,439.1 billion, up 50.4% year-over-year [4] Business Developments - Samsung Biologics secured a KRW 1.1 trillion manufacturing agreement with a European pharmaceutical company in Q4 2025, contributing to a cumulative contract value exceeding USD 21 billion [5] - The company reaffirmed its strategic direction as a pure-play CDMO and plans to begin revenue contributions from Plant 5 in 2026 [6] - The company projects annual revenue growth of 15-20% for 2026, excluding potential contributions from the planned U.S. site acquisition [6] Infrastructure and Capacity Investments - Samsung Biologics announced plans to acquire a U.S. manufacturing facility in Rockville, Maryland, which includes two CGMP manufacturing plants with a combined capacity of 60 kL [7] - The company also secured land for Bio Campus III to support future expansion and next-generation modalities [8] - Investments are being made to enhance operational systems and digital capabilities across its facilities [9] Environmental, Social, and Governance (ESG) Initiatives - Samsung Biologics received an 'A' rating in Water Security from the Carbon Disclosure Project (CDP) and is committed to sustainable healthcare manufacturing practices [10]